Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 9212345...102030...Last »

Recent Hack of Sangamo Therapeutics Exec Underlines Increased Risk for Biopharma

Sangamo Therapeutics recently filed a notice with the U.S. SEC describing a data security breach.

Read More »

Pharma Sales Drive J&J’s 2018 First Quarter

Johnson & Johnson reported a strong first-quarter 2018 with $20 billion in sales that was fueled by significant growth in the company’s pharmaceuticals business.

Read More »

Sanofi to Sell Generics Division to Advent

Paris-based Sanofi agreed to sell the company’s generics division Zentiva to the private equity firm Advent International for 1.9 billion euros ($2.4 billion). The deal is expected to wrap by year-end 2018.

Read More »

Shire Sells Oncology Business to France’s Servier for $2.4 Billion

Shire, a global biotechnology company focused on rare diseases, sold its oncology business to France’s Servier for $2.4 billion.

Read More »

Boehringer Ingelheim, Lilly Announce Academic Collaboration With University Of Oxford

Boehringer Ingelheim and Eli Lilly announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes.

Read More »

Rigel Website Shows Erroneous Information About Tavalisse Winning FDA Approval

Rigel Pharmaceuticals’ website erroneously claimed the company’s drug candidate Tavalisse gained approval from the U.S. FDA.

Read More »

Bristol-Myers, Harvard Stem Cell Institute Team Up

Bristol-Myers Squibb and the Harvard Fibrosis Network, part of the Harvard Stem Cell Institute, launched a collaboration to discover and develop new therapies for fibrotic diseases.

Read More »

GSK divesting rare disease gene therapy drugs

GlaxoSmithKline is divesting its rare disease gene therapy drugs to private biotech company Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker’s pharmaceuticals portfolio.

Read More »

U.S. judge schedules 2019 trial in opioid litigation

A federal judge pushing for a settlement in lawsuits seeking to hold drug companies responsible for their roles in the U.S. opioid epidemic set an aggressive schedule that would have the first trial take place in March 2019.

Read More »

CVS rolls out new tool to combat rising drug prices

Drugstore chain CVS Health Corp. launched a new tool that will allow pharmacies help customers tackle the soaring cost of drugs by comparing prices of medicines.

Read More »

Alex ion snaps up Wilson for $855 million

Alex ion Pharmaceuticals agreed to buy Sweden’s Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million).

Read More »

Illumina and Loxo Oncology Join Forces to Develop Pan-Cancer Companion Diagnostics

Illumina is teaming up with Loxo Oncology to develop and commercialize a multi-gene panel for broad cancer profiling.

Read More »

Mylan to buy MS drug marketing rights from Israel’s Mapi Pharma

Mylan NV will buy global marketing rights to an experimental multiple sclerosis treatment from Israel’s Mapi Pharma, aiming to strengthen its position in the market for MS drugs and counter falling sales of the emergency allergy shot EpiPen.

Read More »

New Pfizer HQ to be located in The Spiral in Manhattan

Pfizer signed a 20-year lease for the company’s new global headquarters at The Spiral, an office tower being built by Tishman Speyer at 66 Hudson Boulevard at Hudson Yards of Manhattan.

Read More »

Roche Secures U.K. NHS Coverage Nod for Tecentriq, Completes Flatiron Acquisition

Swiss pharma giant Roche has completed the acquisition of Flatiron Health and secured a big win with the United Kingdom’s healthcare provider for the lung cancer drug Tecentriq.

Read More »

Novartis Acquires AveXis for $8.7 Billion

Swiss-based Novartis struck a deal to acquire Bannockburn, Illinois-based AveXis for $8.7 billion. Novartis will pay $218 per share.

Read More »

Ionis may get up to $300 million in licensing deal with AstraZeneca

Ionis Pharmaceuticals Inc. said on Monday a licensing deal for the company’s fatty liver disease treatment with AstraZeneca Plc could fetch up to $300 million in milestone payments.

Read More »

New Jersey health officials investigating potential E.coli outbreak

Health officials in New Jersey are investigating an E. coli outbreak in four counties that left at least eight people hospitalized.

Read More »

J&J loses trial over claims linking cancer to asbestos in talc

Johnson & Johnson suffered the company’s first trial loss in a lawsuit claiming its talc-based products including Johnson’s Baby Powder contain cancer-causing asbestos, with a New Jersey jury ordering J&J and another company to pay $37 million in damages.

Read More »

U.S. Medicare sets outpatient rate for Yescarta reimbursement

Medicare will pay hospitals close to its standard mark-up rate for administering the cell therapy Yescarta for cancer outpatients, who will have a co-payment of nearly $80,000, according to the Centers for Medicare & Medicaid Services (CMS).

Read More »

Page 1 of 9212345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation